Compare Moderna, Inc. (MRNA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Western Alliance Bancorporation — how do they compare? Moderna, Inc. trades at $137.05 (market cap $56.02B), while Western Alliance Bancorporation trades at $79.37 (market cap $8.72B). The key difference: Moderna, Inc. is far larger — about 6.4× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.1% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WAL | |
|---|---|---|
Market Cap | $56.02B | $8.72B |
Sector | Health | Financials |
52-Week High | $174.38 | $96.08 |
52-Week Low | $22.36 | $66.70 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Western Alliance Bancorporation (WAL) trades at $79.94, down 1.25% on the day, with a bearish technical signal despite strong fundamentals. The bank reported Q2 2026 earnings that met revenue expectations but slightly missed EPS estimates, while maintaining robust profitability with a 25.43% net income margin and 13.43% ROE. Recent developments include the launch of WA VenueX™ digital asset platform and recognition as Arizona's #1 bank by Forbes.
WAL presents a compelling value opportunity with a P/E of 9.02 and strong analyst support (79% buy ratings, $93.86 consensus target), though negative operating cash flow and bearish technical indicators warrant caution. The stock offers 17% upside to consensus target but faces headwinds from declining cash flow and mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
